Trials / Unknown
UnknownNCT05233982
MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer
MITO 35a: A Multicenter, Prospective, Single Arm Trial of Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wildtype Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- National Cancer Institute, Naples · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a multicenter, prospective, phase II single arm, open-label trial in which patients with newly diagnosed advanced epithelial ovarian, primitive peritoneal, and fallopian tube cancer BRCA wild type, in partial or complete response to first line platinum-based chemotherapy, receive Olaparib maintenance therapy (300 mg, tablets formulation twice daily).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olaparib Oral Product | Olaparib Maintenace Treatment after first line platium based chemotherapy in BRCA wilde-type ovarian cancer patients |
Timeline
- Start date
- 2021-12-09
- Primary completion
- 2026-01-01
- Completion
- 2026-01-01
- First posted
- 2022-02-10
- Last updated
- 2023-03-24
Locations
5 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT05233982. Inclusion in this directory is not an endorsement.